Continuing improvements in HIV treatment are helping many people with HIV lead healthy lives, but some HIV-positive people may not be well-enough informed about the latest treatment options, the National Association of People Living with HIV/AIDS (NAPWA) has said in a statement to mark the launch of an innovative new HIV treatments information project.

John Daye, NAPWA's Health, Treatments & Research Portfolio Co-Convenor reports from the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston, USA from 3-6 February 2008

A major HIV/AIDS medical conference in Sydney has generated lots of news on the treatments front, reports Paul Kidd.

The evolution of HIV medicine over the last quarter century has led to answers for many of the big questions about how to treat people living with HIV. In 2007, we know that using multiple drugs from different classes, maintaining adherence to dosing schedules and being responsive to side effects and toxicities are all key parts of the broad response to HIV.

Non-nucleosides are a powerful option for treating HIV, but cross-resistance can mean you only get one bite of the cherry. This is the final instalment in a three-part series looking at key drug classes.

Nucleoside analogues are the backbone of successful anti-HIV treatments. This article examines some of the issues involved in selecting the best nucleoside backbone.

Thirty-two quick and easy strategies to help you take your medications on time.

!(thumbnail)/files/atpafs_arv_thumb.jpg( )! This ATPA fact sheet is a quick reference to the factors people with HIV and their doctors need to consider when choosing an antiretroviral treatment regimen.

PL's resident medical expert, Dr Nick Medland, answers readers' letters about missing doses, starting treatments and sexually-transmitted infections.

The registrar pops out of the room. Five minutes is an eternity when you are in a hospital treatment room and don’t know what’s happening on the other side of that big mauve door.